Announcement PDF Page | 1 ImpediMed Limited Suite 31C, 12-18 Tryon Rd Lindfield NSW 2070 Australia E: investorrelations@impedimed.com W: impedimed.com 24 September 2026 Companies Announcements Office Australian Securities Exchange Update on Options ImpediMed Limited (ASX: IPD) (ImpediMed or the Company) refers to its equity capital raising transaction announced on 4 May 2026, which included an issue of options (the Attaching Options and Follow-On Options) to participants in the capital raising and its update to shareholders on the quotation status of those options on 26 June 2026. Engagement with ASX As outlined in the prospectus for the capital raising dated 4 May 2026 and the related notice of EGM dated 13 May 2026, the Company applied to ASX to have both the Attaching Options and the Follow-On Options quoted on the ASX. ASX approved quotation of the Attaching Options on 18 June 2026, which options are tradeable on the ASX under ASX code IPDO. ASX determined not to quote the Follow-On Options, which options can be transferred via off-market trade. Following ASX's determination, the Company engaged with ASX to explore potential enhancements to the current option structure but following that engagement and careful consideration of potential alternatives, the Company has determined not to pursue any changes to the quotation status of the Attaching Options and Follow-On Options or otherwise seek to implement an alternative option structure. In making that determination, the Board assessed a number of potential alternatives, each of which would have required considerable resources to pursue and none of which presented a certain pathway to implementation, and took into account the expiry of the Attaching Options on 31 March 2027. Having regard to these matters, the Company has determined to continue administering the Attaching Options and Follow-On Options in accordance with their existing terms and conditions and quotation status. Option terms Investors should refer to the prospectus dated 4 May 2026 for the complete terms of the Attaching Options and Follow-On Options. In particular, the prospectus outlines that: Page | 2 • the Attaching Options and Follow-On Options are not stapled; • purchasing an Attaching Option does not carry an entitlement to a Follow-On Option, such that each must be acquired independently; and • an Attaching Option may be exercised regardless of whether the holder holds a Follow- On Option; however, a holder of Follow-On Options may exercise those options only if they have exercised at least that number of Attaching Options. If a holder of an Attaching Option or a Follow-On Option is uncertain about how the options operate or apply to their circumstances, the Company recommends that such holder should seek independent professional advice. For more information, please contact Investor Relations at investorrelations@impedimed.com. Approved for release by the Board of ImpediMed Limited About ImpediMed Headquartered in Sydney, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally. In March 2024, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines® ) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex® , ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed’s SaaS subscription-based business. For more information, visit www.impedimed.com.